comparemela.com

Malignant Secondary Lung Neoplasm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Certain NSCLC Subgroups May Not Benefit From Immunotherapy

A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.

United statesSan franciscoMark gramlingSociety for immunotherapy of cancerLung cancerUng carcinomaAncer lungBiologic therapyNon small cell lung cancerBrain metastasisMetastatic brain tumorMalignant head and neck neoplasmMalignant secondary lung neoplasmEtastasis lungSmall cell lung cancerAlignant neoplasia

Benefits of Tebentafusp in Uveal Melanoma Last 3 Years

A new analysis suggests that the treatment s benefits for overall survival endures for at least 36 months.

France generalOmid hamidTebentafusp kimmtrakInstitut curieLos angelesSophie piperno neumannSinai cancer centerEuropean society for medical oncologyEuropean societyMedical oncologyAnnual congressNew england journalCedars sinai cancer centerMalignant melanomaSkin cancerAlignant skin neoplasm

Selpercatinib Extends PFS in First-line RET-Positive NSCLC

A randomized trial found that selpercatinib improved PFS by more than two-fold, but overall survival data remain immature.

Eli lillyFung loongEuropean society for medical oncologyChinese university of hong kongHerbert ho fung loongChinese universityHong kongMedical oncologyNew england journalNon small cell lung cancerLung cancerUng carcinomaAncer lungBrain metastasisMetastatic brain tumorMalignant head and neck neoplasm

ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC

Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs chemotherapy in resected stage IB-IIIA NSCLC. But will early DFS results extend to overall survival?

University of chicagoUnited statesMarina garassinoPeter maccallum cancer centreThoracic oncology programEuropean society for medical oncologyBen solomonEuropean societyMedical oncologyAnnual meetingLung cancerUng carcinomaAncer lungNon small cell lung cancerAnaplastic lymphoma kinase alk inhibitorAlk inhibitors

Time for Personalized Radiation Therapy in Lung Cancer?

A phase 2 study supports customized lung stereotactic ablative radiotherapy for a variety of scenarios and tumor sizes.

United statesStanford universityVivek vermaMichael gensheimerUniversity of texas md anderson cancer centerGlobal centerStanford university school of medicineHokkaido university faculty of medicineDepartment of radiation oncologyCancer centerRadiation oncologyStanford university schoolBiomedical scienceHokkaido university facultyLung cancerUng carcinoma

vimarsana © 2020. All Rights Reserved.